

10-th Webinar of the mSTR Virtual Medical Concilium

Simultaneous Integrated Diagnostic Testing for COVID-19 and Tuberculosis

Nana Kiria Rusudan Aspindzelashvili National Center for Tuberculosis and Lung Diseases Tbilisi, Georgia 15.10.2021



- As the world comes together to fight against the COVID-19 pandemic, it is important to ensure that essential services and operations addressing long-standing health care problems continue to protect lives of people with TB and other diseases or health conditions
- Health services, including national tuberculosis programs, must actively participate in effective and rapid response to COVID-19, while ensuring continuous provision of TB services



Before the COVID-19 pandemic, tuberculosis (TB) had been the leading cause of death from the communicable diseases worldwide. Despite some great progress made by the high TB burden countries over the past few years in TB detection and treatment, there was a sharp decline in TB case notification rate in 2020 due to the COVID-19 pandemic



Tuberculosis and COVID-19 Similarities and Differences

	Tuberculosis	COVID-19
Symptoms	 General Subfebrile temperature Weight loss Night sweats Lung-specific Cough Shortness of breath Chest pain and hemoptysis 	 Fever Cough (usually dry) Sore throat Shortness of breath. Loss of smell and taste Shortness of breath (severe acute respiratory distress syndrome, more common in the 2nd week of illness)

Tuberculosis and COVID-19





Tuberculosis and COVID-19 interaction: A review of biological, clinical and public hear effector Danization Viscaa, b, 1, C.W.M. Ong c, d, 1, S. Tiberi e, f, R. Centis g, L. D'Ambrosio h, B. Chenc, J. Mueller i Produeller i, R. Duartej, k, M. Dalcolmol, G. Sotgiu m, G.B. Migliori g, *, D. Goletti n

COVID-19	ТВ			
Recent (months)	Ancient (millennia)			
Significant burden	Significant burden			
Droplet transmission of SARS-CoV-2.	Droplet transmission of <i>M</i> . tuberculosis bacterium.			
- Fever or chills	- Coughing with mucus or blood			
 Cough, shortness of breath or difficulty breathing Fatigue and headache Muscle or body aches New loss of taste or smell 	 Coughing that lasts more than 2 months Chest pain Loss of appetite Weight loss 			
 Sore throat, congestion, or runny nose 	Chills, fever, or night sweats			
 Nausea, vomiting, or diarrhea Cancer 	- Fatigue - Cancer			
 Chronic Kidney Disease Chronic Lung Diseases Obesity Heart Conditions Sickle Cell Disease Immunocompromised State Type 2 Diabetes Mellitus 	 Chronic Lung Diseases Smoking Alcohol Use Disorders Depression HIV Immunocompromised State Type 2 Diabetes Mellitus 			
	Recent (months) Significant burden Droplet transmission of SARS-CoV-2. - Fever or chills - Cough, shortness of breath or difficulty breathing - Fatigue and headache - Muscle or body aches New loss of taste or smell - Sore throat, congestion, or runny nose - Nausea, vomiting, or diarrhea - Cancer - Chronic Kidney Disease - Obesity - Heart Conditions - Sickle Cell Disease - Immunocompromised State			



Table (continuation)

Locreasing Vulnerability	- Cancer	- Cancer	1
	- Chronic Kidney Disease	- Chronic Lung Diseases	
	- Chronic Lung Diseases	- Smoking	
	- Obesity	- Alcohol Use Disorders	
	- Heart Conditions	Depression	
	- Sickle Cell Disease	– HIV	
	- Immunocompromised State	 Immunocompromised State 	
	- Type 2 Diabetes Mellitus	- Type 2 Diabetes Mellitus	

Availability of rapid diagnostics Yes

Yes

REVIEW ARTICLE

Tuberculosis and COVID-19 interaction: A review of biological, clinical and public health effects



D. Visca^{a,b,1}, C.W.M. Ong^{c,d,1}, S. Tiberi^{e,f}, R. Centis^g, L. D'Ambrosio^h, B. Chen^c, J. Muellerⁱ, P. Muellerⁱ, R. Duarte^{j,k}, M. Dalcolmo^l, G. Sotgiu^m, G.B. Migliori^{g,*}, D. Golettiⁿ

Active tuberculosis, sequelae and COVID-19 coinfection: first cohort of 49 cases

Marina Tadolini, Luigi Ruffo Codecasa, José-María García-García, François-Xavier Blanc, Sergey Borisov, Jan-Willem Alffenaar, Claire Andréjak, Pierre Bachez, Pierre-Alexandre Bart, Evgeny Belilovski, José Cardoso-Landivar, Rosella Centis, Lia D'Ambrosio, María-Luiza De Souza-Galvão, Angel Dominguez-Castellano, Samir Dourmane, Mathilde Fréchet Jachym, Antoine Froissart, Vania Giacomet, Delia Goletti, Soazic Grard, Gina Gualano, Armine Izadifar, Damien Le Du, Margarita Marín Royo, Jesica Mazza-Stalder, Ilaria Motta, Catherine Wei Min Ong, Fabrizio Palmieri, Frédéric Rivière, Teresa Rodrigo, Denise Rossato Silva, Adrián Sánchez-Montalvá, Matteo Saporiti, Paolo Scarpellini, Frédéric Schlemmer, Antonio Spanevello, Elena Sumarokova, Eva Tabernero, Paul Anantharajah Tambyah, Simon Tiberi, Alessandro Torre, Dina Visca, Miguel Zabaleta Murguiondo, Giovanni Sotgiu, Giovanni Battista Migliori

□First cohort of patients with TB/COVID-19 (GTN): 49 cases from 8 countries

□Mean age: 48 years

□ Males: 82%

□Migrants: 50%

□Vaccinated (BCG): 63%

□HIV +: 12.5%

□TB diagnosed first: 26 (53.0%)

□COVID-19 diagnosed first; 14 (28.5%)

□Both diseases diagnosed at the same time: 9 (18,3%)

□ Active TB: 42 (85.7%)

□TB sequelae: 7 (14.3%)



Global TB and COVID-19 study by the Global Tuberculosis

700 cases from 40 countries were analyzed

- □TB was diagnosed before COVID-19 diagnosis in 44.0% (302/686) of patients [median (IQR) 79 (38-141) days];
- COVID-19 was diagnosed before TB diagnosis in 9.7% [67/686 , median (IQR) 28 (15-40) days]
- TB and COVID-19 diagnosed simultaneously in 17.6% [121/686]
- **TB** sequelae in 28.6% [196/686]

Global TB and COVID-19 Study by the Global Tuberculosis Network (GTN



tuberculosis			N(%)		
males		508/706			
Median(IQR) age, ears at last birthday(n=377)		44(30-58			
TB form	New case		560/662(84.6)		
	Relapse		56/662(8,5)		
	Lost to follow-u	qu	29/662(4.5)		
	Failure		17/662(2.6)		
Pulmonary TB			600/694(86,5)		
TB laboratory confirmed			564/671(84,1)		
Solid culture			382/578(66,1)		
Liquid culture			306/578(52,9%)		
Xpert MTB/RIF			383/578(66,3%)		
First line LPA		105/578 (1,8)			
Second line LPA		28/578(4,8)			
TB drug resistance pattern at TB diagnosis Pan-susceptible TB		Pan-susceptible TB	474/561(84.5)		
Drug-resistant TB		85/561(15,5)			



Global TB and COVID-19 Study by the Global Tuberculosis Network (GTN)

Covid-19 signs and symptoms	n(%)	Covid-19 signs and symptoms	n(%)
Abdominal pain	34/498 (6,8%)	Myailgia	74/498(14,9%)
Arthralgia	36/498(7,2%)	Nasal congestion	65/498 (13,1%)
Chest pain	85/498(17,1%)	Olfactory disorders	45/498 (9,0%)
Diarrhoea	47/498 (9,4%)	Shortness of breath	182/493 (36,5%)
Dry cough	293/498 (58,8%)	Sore throat	85/498 (17,1%)
Fever	358/498 (71,9%)	Taste disorders	42/498 (8,4%)
Headache	119/498 (23,9%)	Tiredness	101/498 (20,3%)
Confusion	33/498 (6,6%)	Vomiting/nausea	34/498(6,8%)
Malaise	85/498 (17,1%)	Other symptoms	59/498 (11.85%)



Global TB and COVID-19 Study by the Global Tuberculosis Network (GTN)

Radiology and COVID-19 diagnosis	n(%)
CT scan	109/601 (18,1)
Chest X-ray	206/601 (34,3)
CT scan and Chest X-ray	156/601 (26,0)
Not done	130/601(21,6)
Unilateral pulmonary cavitary, lesions	39/355 (11,0)
Bilateral pulmonary cavitary, lesions	56/355 (15,8)
Unilateral pulmonary infiltrate, (no cavities)	64/355 (18,0)
Bilateral pulmonary infiltrate, (no cavities)	149/355 (42,0)
Other chest x-ray findings	48/355 (13,5)
No lesion	27/355(7,6)
Typical ground glass opacity, unilateral	40/265 (15,1)
Typical ground glass opacity, bilateral	132/265 (49,8)
Atypical opacity	61/265 (23)
No opacity	38/265(14,3)



Global TB and COVID-19 Study by the Global Tuberculosis Network (GTN)

Radiology at TB diagnosis		N(%)
Chest X-ray and or CT scan	549/572	(96,0%)
Non done	23/572	(4,0%)
Unilateral pulmonary cavitary lesions	107/549	(19,5%)
Bilateral pulmonary cavitary lesions	119/549	(21,7%)
Unilateral pulmonary infiltrate (no cavities)	110/549	(20,0%)
Bilateral pulmonary infiltrate (no cavities)	130/549	(23,7%)
Other radiological TB form	97/549	(17,7%)
No lesion	38/549	(6,9%)



Tuberculosis is the deadliest communicable disease worldwide (more than HIV/AIDS), causing about 10 million new cases and 1.5 million deaths each year. TB and COVID-19 are infectious diseases that primarily affect lungs. Both diseases have similar symptoms, such as cough, fever, and shortness of breath. However, testing for COVID-19 or TB should be based on clinical characteristics, history, and local burden of TB to ensure that diagnostic needs of TB patients are not ignored when testing for COVID-19.

Patricia Comella-del-Barrio, Maria Luiza De Souza-Galvão, Cristina Prat-Aymerich, José Domínguez[®] mpact of COVID19 on Tuberculosis Control[®]



- Diagnostic testing is a critical and necessary step to detect and control pathogens of public health significance, including COVID-19 and tuberculosis
- There is an urgent need to expand access to diagnostic testing for both COVID-19 and tuberculosis. A simultaneous integrated approach to testing for COVID-19 and tuberculosis should be used in high TB burden countries



- For both, TB and COVID-19, there are comorbidities or behavioral factors (malnutrition, diabetes, smoking, chronic obstructive pulmonary disease, HIV, etc.) that increase the risk of both diseases.
- There are multiplex diagnostic testing platforms that can test for both *Mycobacterium tuberculosis* and SARS-CoV-2.
- Both diseases require early detection and treatment to improve patient outcomes.





- When a person presents to a health care facility with respiratory symptoms, including cough and difficulty breathing, diagnostic tests for COVID-19 and tuberculosis should be performed simultaneously according to the national diagnostic algorithms.
- Simultaneous integrated testing is especially important for people at higher risk of developing one or both diseases.




- People with respiratory symptoms who have previously tested negative for COVID-19 and have not been diagnosed with COVID-19 should be tested for tuberculosis.
- People with respiratory symptoms who have previously tested negative for tuberculosis and have not been diagnosed with tuberculosis should be tested for COVID-19.

Simultaneous Integrated Testing for COVID-19 and TB in High TB Burden Countries






Bi-directional TB-COVID screening



Guidance note on Bi-directional TB-COVID screening and screening of TB among ILI/SARI cases (INDIA)



TB screening for COVID positive patients:





Recommendations for COVID-19 Testing of (TB/RR-TB) Patients [Georgia]

Testing for COVID-19 should be done	
on patients as soon as they are diagnosed with tuberculosis	COVID-19 test should be performed in all patients regardless of whether or not they have typical symptoms and signs of COVID-19;
on TB patients who are on outpatient treatment	 Prior to the start of chemotherapy; If there has been close contact within the last 14 days with a confirmed or probable case of COVID-19: If the patient has symptoms characteristic of COVID-19, or if the existing symptoms have worsened



Recommendations for COVID-19 Testing of TB Patients [Georgia] -continuation

Testing for COVID-19 should be done	
on TB patients who are on inpatient treatment	 COVID-19 test must be performed on all patients upon admission to the hospital; If the patient develops symptoms characteristic of COVID-19 or if their symptoms have worsened
on patients with LTBI on preventive treatment	 If there has been a close contact within the last 14 days with a confirmed or probable case of COVID-19; In the presence of symptoms characteristic of COVID-19



Nucleic Acid Amplification Tests (NAAT) for Simultaneous Integrated Testing

- The NAATs available for tuberculosis and COVID-19 testing require different types of specimens: sputum is usually required for detection of pulmonary tuberculosis, and nasopharyngeal or oropharyngeal swabs or lavage samples are required for COVID-19
- Countries can improve testing efficacy by using multiplex NAAT platforms that can test for both diseases



 NAAT platforms that can perform WHO-recommended tests for TB and SARS-CoV-2:

- ✓ Cepheid GeneXpert
- ✓ Abbott Realtime
- ✓ Rochecobas 6800/8800
- GeneXpert system is one of the available NAAT platforms capable of detecting tuberculosis and COVID-19; and using Global Fund resources it can be deployed in health care facilities at the peripheral level improving access to care and reducing diagnostic delays



- The COVID-19 pandemic emphasizes the need to document and report test results in real time through integrated dashboards and mobile apps to facilitate access to inform clinical and programmatic decisions on both diseases.
- National testing algorithms, existing testing infrastructure, and existing specimen referral mechanisms should be taken into account when developing a specimen referral system.
- Other considerations should include a mechanism for transferring high priority results electronically.



• Implementation of simultaneous integrated testing will require a coordinated approach to program management.

This would entail

- coordinated development of diagnostic algorithms with the engagement of multiple stakeholders;
- planning and strengthening laboratory capacity to tackle the burden of both diseases;
- following necessary infection prevention and control measures during specimen collection, packaging, transportation, and testing.



TB/COVID 19 Coinfections (GEORGIA)

	TYPE OF TB	2020	2021	TOTAL
	DS	34	76	110
	DR	8	22	30
Total		42	98	140



TB/COVID-19 Coinfections (Georgia)

	2020			2021				
	TB/ COVID	ТВ	COVID% in TB*	COVID% in TB**	TB/ COVID	ТВ	COVID% in TB*	COVID% in TB**
DS-TB	34	1608	2.11%	1.9%	76	965	7.88%	6.9%
DR-TB	9	208	4.33%	0.5%	22	131	16.79%	2.0%
TOTAL	43	1816		2.4%	98	1096		8.9%



Thank you

for

attention!